Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Larry Bock

Joshua Boger

Vertex Pharmaceuticals Incorporated

BridgeBio Pharma is a self-described biopharmaceutical company focused on developing and commercializing transformative medicines for serious diseases. It focuses on gene-based and genetic medicine.

BridgeBio Pharma

CRISPR Biotech Engineering is an early-stage genome editing company that is committed to using innovative CRISPR-Cas9 technology to improve human lives.

CRISPR Biotech Engineering

Eilean Therapeutics is a small molecule oncology drug discovery company that develops pan-variant therapies for hematologic malignancies targeting major drivers of cancer resistance.

Eilean Therapeutics

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. 

Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development.

Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards.

Kymera Therapeutics

CRISPR Therapeutics

J.P. Morgan Securities Inc.

Bank of America Merrill Lynch

Morgan Stanley

Goldman Sachs

Janssen Belgium

Norwest Venture Partners

J.H. Whitney & Co

New Enterprise Associates

Greylock

Vertex Pharmaceuticals

Join us in welcoming Lateefah Spires Brown the new San Diego Learning Lab head, to the Vertex team. 

A lifelong educator, Lateefah has a background in biology and a love for all things science — as a child you could even find her scooping up tadpoles and catching fireflies. 

While it was tough for Lateefah to say goodbye to her high school chemistry students, she is excited to work with the next generation of scientists and researchers at our Learning Lab!

For many job candidates, understanding a company’s commitment to inclusion, diversity and equity is a critical part of the decision-making process. Our Vice President of Talent and Inclusion, Diversity and Equity, Diana Cruz Solash, spoke to BioSpace about how candidates can assess a company’s efforts during a job search. 
 
Some takeaways: 
- Check if the job description mentions/reflects the company’s commitment to inclusion, diversity and equity
- Look for signs that the company actively promotes belonging, community building, and professional development for all employees, e.g., through employee resource groups and career development programs
- See if interviewers bring up inclusion, diversity and equity without being prompted — if not, ask about it and listen closely for how those commitments are embedded in the way that people work with each other and in how the company operates
 
Read more perspective from Diana, including on how Vertex reinforces our inclusion, diversity and equity commitment in interviews and in day-to-day working life: https://lnkd.in/ehCbeFXV

Our Vertexians are celebrating the recent news of FDA approval of our gene-edited treatment for #BetaThalassemia. Vertexian Yamila reflects on what this moment means:

“Often, patients are seeing medical providers who are not thalassemia specialists. So the patient is usually responsible for bringing in that knowledge and then advocating for themselves.” — Pranav Saha, a courageous advocate living with #BetaThalassemia 
 
Hear Pranav break down the importance of self-advocacy for people living with beta thalassemia:

#Breaking The U.S. FDA approves our treatment for #BetaThalassemia. We are thrilled to see this approval provide a new option to eligible patients who have been waiting. Learn more: https://lnkd.in/gBBrWdnK

“Our patients always inspire us to never give up.” Paul Negulescu, Senior Vice President, Research, reflects on the last two decades of our drug discovery process and taking on new challenges.

We’re celebrating the extraordinary life, values and legacy of Dr. Martin Luther King, Jr.  

A transformational leader and advocate for nonviolence and equal rights, Dr. King made an indelible impact in the United States and beyond — earning the Nobel Peace Prize in 1964 for his dedication to civil rights. 

#MLKDay is the only U.S. federal holiday designated as a National Day of Service, and the Vertex Foundation is supporting opportunities for Vertexians to give back in the communities in which we live and work.

We care for and care about our people. 

And we’re honored to be named a Best Adoption-Friendly Workplace by the Dave Thomas Foundation. A recognition that we don’t take lightly, we pride ourselves on offering comprehensive benefits that support families. 

Explore our family-building benefits like adoption, surrogacy and more: https://lnkd.in/e4yB6GNb

“’What if?’ is a powerful question,” says Andre Williams, Head of our Boston Learning Lab.
 
“Our STEAM education programs spark this question in our students by engaging them in hands-on scientific experiments as well as exposure to the wide variety of career paths in the biotech industry. Working with students in our local community makes me excited to see the next generation of scientists get their start.” 

#STEAM #SteamEducation  #STEMeducation #SteamEducator #STEM #HandsOn  #21stCenturySkills

The Saudi Food and Drug Authority (SFDA) approves our treatment for #SickleCellDisease and #BetaThalassemia in the Kingdom of Saudi Arabia. Learn more: https://lnkd.in/epWDX4Z6

Metric
Company Name	Vertex Pharmaceuticals Incorporated	BridgeBio Pharma	CRISPR Biotech Engineering	Eilean Therapeutics
Symbol	VRTX
MSH ID	COM:VRTX	COM:BRIDGEBIOPHARMA	COM:CRISPR-BTE	COM:EILEANTHER
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	US	US	GB	US
Stage		Post-IPO Equity
Employee Count	5.40K
Website	vrtx.com	bridgebiopharma.com	crispr-bte.com	eileanther.com
LinkedIn	vertex-pharmaceuticals
Founders

Metric
Market Cap	126.86B
Enterprise Value
Monthly Web Traffic	127.52K	23.81K
Web Traffic Growth	-0.34	0.19
Valuation
Raised Capital	1.11M	250M

Metric
Revenue	9.84B
Revenue (LTM)
Revenue (NTM)
Gross Profit	8.58B
EBITDA	3.93B
Operating Income	3.75B
Net Income	3.62B
EPS	14.05
Diluted EPS	13.89
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.87
Operating Profit Margin	0.42
EBITDA Margin	0.40
Net Profit Margin	0.39
Return on Equity	0.24
Return on Assets	0.17
Return on Capital Employed	0.21

COM:VRTX

Vertex Pharmaceuticals Incorporated

Last Close

450.37

22/11 21:00

Market Cap

126.86B

Beta: -

Volume Today

1.27M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	31.95
P/B Ratio	6.71
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	12.91
EV Multiple	29.55

Metric
Days Sales Outstanding	58.17
Days Payables Outstanding	116.52
Days Inventory Outstanding	238.25
Operating Cycle	296.80
Cash Conversion Cycle	211.39
Asset Turnover	0.51

Metric
Operating Cash Flow	3.54B
Free Cash Flow	3.28B
Cash Flow to Debt	5.47
Operating Cash Flow/Sales	0.39
Free Cash Flow Yield	0.04

Metric
Cash & Equivalents	10.37B
Accounts Receivable	-84.10M
Inventory	738.80M
Goodwill	1.09B
Debt to Capitalization	0.06
Debt to Assets	0.03
Current Ratio	4.08
Quick Ratio	3.60

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.05
R&D to Revenue	0.31
SG&A to Revenue